US · VIR
Vir Biotechnology, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- San Francisco, CA 94158
- Website
- vir.bio
Price · as of 2025-12-31
$10.00
Market cap 1.26B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $22.15 | +121.5% |
| Intrinsic Value(DCF) | $4.39 | -56.1% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | $0.00 | $0.00 | |||
| 2019 | $45.70 | $40.34 | $2.00 | $0.00 | $14.74 |
| 2020 | $52.82 | $1,421.19 | $41,763.49 | $0.00 | $0.00 |
| 2021 | $21.84 | $268.77 | $3,039.85 | $31.24 | $5,985.01 |
| 2022 | $22.61 | $483.48 | $91,683.63 | $34.99 | $208.74 |
| 2023 | $11.36 | $25.41 | $5.50 | $0.00 | $377.65 |
| 2024 | $7.96 | $20.45 | $3.06 | $0.00 | $19.42 |
| 2025 | $9.34 | $22.15 | $1.25 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Vir Biotechnology, Inc.'s (VIR) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $22.15
- Current price
- $10.00
- AI upside
- +121.5%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$4.39
-56.1% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| VIR | Vir Biotechnology, Inc. | $10.00 | 1.26B | +121% | -56% | — | — | -2.95 | 1.69 | 18.87 | -2.39 | — | 1.75 | 82.92% | -682.68% | -638.87% | -45.73% | -112.47% | -36.47% | 0.24 | — | 5.54 | 5.03 | 0.11 | -1749.00% | -761.00% | -1257.00% | -30.66% | -4.22 | -95.31% | 0.00% | 0.00% | 0.00% | -2.17 | -2.57 | 14.85 | 0.63 |
| DAWN | Day One Biopharmaceutical… | $10.60 | 1.09B | +166% | +52,842% | — | — | -9.99 | 2.43 | 6.78 | -5.99 | -509.45 | 2.53 | 89.12% | -80.76% | -67.85% | -22.74% | 1066.44% | -19.68% | 0.01 | — | 8.02 | 7.73 | 1.84 | 196.00% | 2060.00% | 2964.00% | -9.71% | -1.71 | 884.82% | 0.00% | 0.00% | 6.71% | -4.96 | -6.09 | 4.01 | 8.31 |
| DNA | Ginkgo Bioworks Holdings,… | $6.75 | 408.98M | +75% | -49% | — | +1,219% | -1.25 | 0.77 | 2.30 | -1.51 | — | 0.87 | 81.48% | -185.29% | -183.81% | -51.08% | -55.89% | -25.05% | 0.82 | — | 4.92 | 4.65 | -0.98 | -4649.00% | -2506.00% | -5323.00% | -45.71% | -1.78 | -31.77% | 0.00% | 0.00% | 0.00% | -1.22 | -2.16 | 2.27 | -7.68 |
| GERN | Geron Corporation | $1.68 | 1.07B | +294,119% | -54% | — | — | -6.40 | 3.99 | 14.52 | -5.38 | — | 3.99 | 98.37% | -225.64% | -226.73% | -66.09% | 7931.16% | -35.34% | 0.43 | -9.39 | 5.56 | 5.04 | -0.28 | -1562.00% | 3238692.00% | 3009.00% | -19.62% | -2.48 | 10011.32% | 0.00% | 0.00% | 0.00% | -4.79 | -3.80 | 10.82 | -2.06 |
| IOVA | Iovance Biotherapeutics, … | $3.86 | 1.28B | +666% | -61% | — | — | -3.46 | 1.94 | 5.14 | -3.10 | — | 3.23 | 97.23% | -153.08% | -148.38% | -55.50% | -89.67% | -42.88% | 0.07 | — | 3.20 | 2.74 | 0.32 | -1484.00% | 6060.00% | -764.00% | -24.83% | -2.19 | -75.14% | 0.00% | 0.00% | 4.22% | -2.74 | -3.29 | 4.20 | -1.24 |
| KURA | Kura Oncology, Inc. | $8.73 | 759.66M | — | — | — | — | -3.73 | 1.57 | 12.04 | 0.37 | — | 1.57 | 100.00% | -358.55% | -322.89% | -42.91% | 126.01% | -28.78% | 0.04 | -119.33 | 9.46 | 9.24 | 1.23 | -288.00% | — | -20708.00% | 20.63% | 1.71 | -87.30% | 0.00% | 0.00% | 28.94% | 0.32 | -0.46 | -1.15 | -0.24 |
| LENZ | LENZ Therapeutics, Inc. | $13.49 | 422.1M | — | — | — | — | -10.13 | 2.47 | — | -5.96 | — | 2.47 | 0.00% | — | — | -89.37% | 72.47% | -34.84% | 0.01 | — | 20.36 | 20.09 | 0.38 | -8471.00% | — | -91.00% | -11.88% | -5.71 | 74.02% | 0.00% | 0.00% | 0.00% | -5.06 | -4.95 | — | 26.23 |
| MRVI | Maravai LifeSciences Hold… | $3.56 | 516.14M | +2,414% | -55% | — | +382% | -2.27 | 2.47 | 2.82 | -4.45 | — | -7.64 | 18.30% | -69.20% | -70.41% | -85.84% | -61.48% | -25.95% | 0.17 | -4.79 | 6.60 | 5.40 | 2.35 | -1429.00% | -2834.00% | 21867.00% | -13.50% | -1.28 | -34.44% | 0.00% | 0.00% | 44.99% | -2.66 | -4.84 | 1.84 | 0.89 |
| PRME | Prime Medicine, Inc. | $4.62 | 833.96M | — | -79% | — | — | -1.45 | 1.86 | 95.42 | -0.69 | — | 1.86 | 100.00% | -6787.36% | -6566.61% | -136.88% | -1418.83% | -79.73% | 0.27 | — | 5.58 | 5.02 | 0.72 | -2417.00% | — | -2525.00% | -45.73% | -3.24 | -912.12% | 0.00% | 0.00% | 39.96% | -0.67 | -1.04 | 45.25 | -3.59 |
| REPL | Replimune Group, Inc. | $7.65 | 631.68M | — | — | — | — | -3.38 | 2.01 | — | -1.69 | — | 2.01 | 0.00% | — | — | -62.58% | -1380.14% | -47.60% | 0.18 | -33.15 | 7.95 | 7.82 | 0.14 | -525.00% | — | 409.00% | -23.79% | -3.08 | -1049.44% | 0.00% | 0.00% | 4.35% | -1.64 | -2.15 | — | 0.67 |
| YDES | YD Bio Limited Ordinary S… | $8.58 | 605.07M | — | — | — | — | — | — | — | — | — | — | 30.44% | -286.45% | -276.58% | -42.69% | -84.41% | -39.29% | 0.00 | -1893.69 | 13.18 | 12.91 | 2.43 | -28010000.00% | 4576.00% | 838627.00% | — | -6.98 | -274.13% | — | 0.00% | — | — | — | — | — |
About Vir Biotechnology, Inc.
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
- CEO
- Marianne De Backer
- Employees
- 408
- Beta
- 1.69
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($4.39 ÷ $10.00) − 1 = -56.1% (DCF, example).